SequelSEC

Zivo Bioscience, Inc. ZIVO

Biological Products, (No Diagnostic Substances) · CIK 0001101026 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$157.22K
Fiscal year ended 2024-12-31
Operating income
-$13.36M
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

Zivo Bioscience, Inc. (ZIVO) reported revenue of $157.22K and net income of -$13.38M for the fiscal year ended 2024-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Zivo Bioscience, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Zivo Bioscience, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Revenue$157.22K$27.65K$0$0$20.00K$0$0$0$0Unavailable
Cost of revenue$108.27K$16.04K$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profit$48.95K$11.61K$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$13.36M-$7.26M-$8.73M-$8.65M-$8.56M-$8.35M-$6.13M-$6.33M-$3.49MUnavailable
Net income-$13.38M-$7.78M-$8.75M-$8.76M-$9.11M-$11.51M-$14.64M-$10.04M-$6.06MUnavailable
Research & development$3.13M$1.38M$2.24M$1.95M$3.75M$2.31M$2.81M$2.38M$788.97KUnavailable
Weighted-average diluted sharesshares 3.17Mshares 1.69MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-4.23$-4.60UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.28M$5.90M$6.49M$6.69M$4.82M$4.08M$1.35M$2.13M$832.24KUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Zivo Bioscience, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Cash & equivalentsUnavailableUnavailable$1.80M$8.90M$137.86K$346.11K$388.89K$317.14K$506.99KUnavailable
Total assets$1.64M$555.72K$2.12M$8.99M$220.18K$369.39K$411.51K$332.28K$737.29KUnavailable
Current assets$1.64M$425.38K$1.90M$8.96M$167.82K$369.39K$411.51K$332.28K$520.42KUnavailable
Total liabilities$2.16M$2.76M$2.13M$2.95M$11.53M$8.71M$22.69M$16.64M$14.36MUnavailable
Current liabilities$2.04M$2.76M$2.03M$2.95M$11.39M$8.71M$22.69M$4.56M$11.18MUnavailable
Total equity incl. NCI-$514.90K-$2.21M-$10.62K$6.04M-$11.31M-$8.34M-$22.28M-$16.30M-$13.62MUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$2.21K$3.74K$0UnavailableUnavailable$0UnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$547.09K$993.09K$490.67K$654.33K$1.56M$1.37M$422.43K$541.71K$666.36KUnavailable

Cash flow

Zivo Bioscience, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Operating cash flow-$4.31M-$5.80M-$7.10M-$6.80M-$2.59M-$3.71M-$5.01M-$4.24M-$2.54MUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0$0$0$0$0$0$0$0$0Unavailable
Financing cash flow$5.58M$4.28M$0$15.57M$2.38M$3.66M$5.08M$4.05M$3.03MUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$490.40KUnavailable
Stock-based compensation$1.51M$89.50K-$297.65K-$104.60KUnavailableUnavailable$87.51KUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable$0$0$0$0$18.75K$25.00KUnavailable

Derived

Zivo Bioscience, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin31.1%42.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-8498.9%-26267.7%UnavailableUnavailable-42778.4%UnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue961.1%323.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.80x0.15x0.94x3.04x0.01x0.04x0.02x0.07x0.05xUnavailable
Revenue YoY growth468.6%UnavailableUnavailable-100.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-8513.4%-28127.2%UnavailableUnavailable-45528.6%UnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenue1994.0%4980.2%UnavailableUnavailable18774.6%UnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZIVO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-K · Filed 2025-03-18View SEC filing
10-Q · Filed 2024-11-14View SEC filing
10-Q · Filed 2024-08-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2015-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2015-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.